Vertex Pharmaceuticals Inc

VRTX.US
Healthcare · Biotechnology
490.39
+11.39 (+2.38%)
USD · NASDAQ

Company Information

Company Name
Vertex Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US92532F1003
CIK: 0000875320
CUSIP: 92532F100
Currency: USD
Full Time Employees: 6,400
Phone: 617 341 6100
Fiscal Year End: December
IPO Date: Jul 24, 1991
Description:

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Address:

50 Northern Avenue, Boston, MA, United States, 02210

People

Directors & Officers

Name Title Year Born
Dr. Jeffrey Marc Leiden M.D., Ph.D. Executive Chairman 1956
Dr. Reshma Kewalramani FASN, M.D. CEO, President & Director 1973
Mr. Charles F. Wagner Jr. Executive VP, COO & CFO 1968
Mr. Amit K. Sachdev J.D. Executive VP & Chief Patient and External Affairs Officer 1968
Dr. Ourania Tatsis Ph.D. Executive VP and Chief Regulatory & Quality Officer 1970
Dr. Carmen Bozic M.D. Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer 1963
Ms. Kristen C. Ambrose CPA Senior VP & Chief Accounting Officer 1977
Dr. Mark Bunnage D.Phil Executive VP & Chief Scientific Officer 1969
Ms. Susie Lisa C.F.A. Senior Vice President of Investor Relations NA
Ms. Joy Liu J.D. EVP, Chief Legal Officer & Corporate Secretary 1978

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 01, 2026 Joy Liu N/A Sale 978.00 $449.17 $439.29K
Mar 13, 2026 Carmen Bozic N/A Sale 2.33K $481.79 $1.12M
Feb 25, 2026 Amit Sachdev N/A Sale 1.85K $486.35 $897.80K
Feb 25, 2026 Duncan Mckechnie N/A Sale 4.91K $487.65 $2.39M
Feb 25, 2026 Edward Morrow Atkinson III N/A Sale 668.00 $486.35 $324.88K
Feb 25, 2026 Jonathan Biller N/A Sale 945.00 $486.35 $459.60K
Feb 25, 2026 Kristen Ambrose N/A Sale 223.00 $486.35 $108.46K
Feb 25, 2026 Mark E Bunnage N/A Sale 620.00 $486.35 $301.54K
Feb 25, 2026 Ourania Tatsis N/A Sale 260.00 $486.35 $126.45K
Feb 19, 2026 Amit Sachdev N/A Sale 58.61K $468.83 $27.48M
Feb 13, 2026 Ourania Tatsis N/A Sale 1.50K $499.99 $749.99K
Feb 11, 2026 Mark E Bunnage N/A Sale 2.02K $460.43 $930.53K
Feb 11, 2026 Ourania Tatsis N/A Sale 466.00 $460.43 $214.56K
Feb 11, 2026 Kristen Ambrose N/A Sale 1.38K $460.43 $633.55K
Feb 11, 2026 Jonathan Biller N/A Sale 1.93K $460.43 $886.33K
Feb 11, 2026 Edward Morrow Atkinson III N/A Sale 1.75K $460.43 $806.21K
Jan 29, 2026 David Taylor N/A Sale N/A $475.68 N/A
Jan 07, 2026 Ourania Tatsis N/A Sale 4.50K $474.99 $2.14M
Jan 06, 2026 Charles F Wagner Jr N/A Sale 9.53K $461.00 $4.39M
Dec 03, 2025 Charles F Wagner Jr N/A Sale 14.00K $456.00 $6.38M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Capital World Investors 25.37M Mar 31, 2026 10.00% $1.55 -0.56%
Vanguard Group Inc 24.11M Dec 31, 2025 9.50% $0.16 -0.46%
BlackRock Inc 23.97M Mar 31, 2026 9.44% $0.19 0.92%
Capital Research Global Investors 21.13M Mar 31, 2026 8.32% $1.46 22.00%
Vanguard Capital Management, LLC 16.51M Mar 31, 2026 6.51% $0.18 0.00%
State Street Corp 11.73M Mar 31, 2026 4.62% $0.18 0.35%
Amvescap Plc. 7.89M Mar 31, 2026 3.11% $0.34 0.51%
JPMorgan Chase & Co 7.03M Mar 31, 2026 2.77% $0.20 16.45%
Geode Capital Management, LLC 6.14M Mar 31, 2026 2.42% $0.17 2.64%
Vanguard Portfolio Management, LLC 5.15M Mar 31, 2026 2.03% $0.12 0.00%
Capital Research & Mgmt Co - Division 3 5.13M Mar 31, 2026 2.02% $0.54 8.29%
Loomis, Sayles & Company LP 4.00M Mar 31, 2026 1.58% $2.41 -0.74%
AllianceBernstein L.P. 3.91M Mar 31, 2026 1.54% $0.57 -13.03%
Wellington Management Company LLP 3.21M Mar 31, 2026 1.27% $0.27 -15.94%
Morgan Stanley - Brokerage Accounts 3.19M Mar 31, 2026 1.26% $0.09 2.20%
NORGES BANK 3.18M Dec 31, 2025 1.25% $0.15 -11.28%
UBS Asset Mgmt Americas Inc 3.06M Mar 31, 2026 1.20% $0.28 1.89%
Bank of America Corp 2.88M Mar 31, 2026 1.13% $0.09 -2.00%
Jennison Associates LLC 2.74M Mar 31, 2026 1.08% $0.84 -15.68%
ClearBridge Advisors, LLC 2.70M Mar 31, 2026 1.06% $1.05 -5.57%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Capital Group Growth Fnd of Amer Comp 13.93M 5.49% ▲ 7.32% Mar 31, 2026
2 American Funds Growth Fd of Amer A 12.54M 4.94% ▼ 9.98% Jun 30, 2026
3 Vanguard Total Stock Mkt Idx Inv 8.06M 3.18% ▼ 0.33% Jun 30, 2026
4 Vanguard 500 Index Investor 6.59M 2.60% ▼ 0.87% Jun 30, 2026
5 Capital Group Investment Co of Amer Comp 6.27M 2.47% ▲ 0.00% Jun 30, 2026
6 American Funds Invmt Co of Amer A 6.27M 2.47% ▲ 0.00% Jun 30, 2026
7 American Funds American Balanced A 5.56M 2.19% ▼ 6.28% Jun 30, 2026
8 Invesco QQQ Trust 5.39M 2.12% ▼ 0.78% Jun 30, 2026
9 Capital Group AMCAP Composite 4.65M 1.83% ▲ 0.66% Jun 30, 2026
10 American Funds AMCAP A 4.65M 1.83% ▲ 0.66% Jun 30, 2026

Financial Highlights

Market Cap: $124.46B
EBITDA: $4.98B
P/E Ratio: $28.41
PEG Ratio: $1.62
Book Value: $76.18
Earnings/Share: $17.26
Profit Margin: 35.51%
Operating Margin: 38.13%
ROA (TTM): 12.14%
ROE (TTM): 24.20%
Revenue (TTM): $12.22B
Revenue/Share (TTM): $47.91
Earnings Growth (YOY): 61.40%
Revenue Growth (YOY): 7.80%

Valuation Metrics

Enterprise Value: $119.20B
Trailing P/E: 28.41
Forward P/E: 24.75

Shares Statistics

Shares Outstanding: 253.81M
Shares Float: 253.04M
% Insiders: 20.60%
% Institutions: 10,004.30%
Short % Float: 2.22%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$12.07B
Cost of Goods Sold
adjust
$-1.81B
Gross Profit
subtotal
$10.27B
SG&A
adjust
$-1.75B
R&D
adjust
$-3.75B
Operating Income
subtotal
$4.76B
Other / Non-Operating Items
adjust
$-807.50M
Net Income
subtotal
$3.95B

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VRTX.US!